top of page

Research Spend Report

Spend by Cancer52 members looked at separately from NCRI partners.


Analysis of the data showed that Cancer52 members spent £23,674,012 on rare and less common cancer research. This did not include the small percentage spent on non-site specific and more common cancers.

Cancer52 member spend by cancer group

Analysis on research spend by cancer group show Blood cancers received the most funding representing of 44% of the total spend in less common cancers (excluding non-site specific and more common cancers). This was followed by Brain and Nervous System which represented 35%. Both Gastrointestinal and cancer sites not included in cancer groups make up 6%. For Gynaecological cancer and Head and Neck both represents 3% while Urological cancer represents 2%.

Given the relatively low numbers for some cancer types, funding has been collated into NCRI cancer site groupings, rather than divided into separate cancer types for Cancer52 members.

Research spend by NCRI cancer group and research area


Cancer52 member spend by research category

Further breakdown by research category shows three areas of research received the most funding: Biology at 23.7%, Early detection, Diagnosis, and Prognosis at 20.1% and Treatment at 45.6%. The less funded area of research comes from Prevention, Aetiology and Cancer Control, Survivorship and Outcomes Research.


Area of research spend per cancer group show

  • Blood is predominately funded towards Biology and Treatment

  • Brain and Nervous System is funded towards Treatment

  • For Gastrointestinal, Gynaecological, Head and Neck and Others its research is funded towards Treatment

  • For Urological it’s funded towards Early detection, Diagnosis, and Prognosis.

Analysis in context

As Cancer52 members account for a lesser amount of research spend in this analysis, patterns around research spend in rare and less common cancers cannot be extrapolated from Cancer52 member figures alone. However, patterns in spend by Cancer52 members seem to be generally similar to the greater NCRI partner spend.

bottom of page